Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | NCF1 | P14598 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14017802 | 0.89 | SMN1; SMN2 (0.46) | SMN1; SMN2CHRM1CHRM3CHRM2NPC1 | |
| SCHEMBL13162853 | 0.89 | KMT2A (0.36) | SMN1; SMN2CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL13561507 | 0.89 | KMT2A (0.36) | SMN1; SMN2CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL18912346 | 0.89 | KMT2A (0.36) | SMN1; SMN2CHRM1CHRM3CHRM2CHRM4 | |
| SCHEMBL9030310 | 0.89 | NPC1 (0.38) | CHRM1CHRM2KDM4EMAPTNPC1 | |
| SCHEMBL27396399 | 0.85 | NPC1 (0.38) | CHRM1CHRM2KDM4EMAPTNPC1 | |
| SCHEMBL23603064 | 0.84 | KDM4E (0.33) | KDM4EMAPT | |
| SCHEMBL21468985 | 0.84 | LIPC (0.41) | CHRM1CHRM3CHRM2CHRM4CHRM5 | |
| SCHEMBL14886377 | 0.83 | LIPC (0.39) | SMN1; SMN2NCF1 | |
| SCHEMBL14886385 | 0.83 | LIPC (0.39) | SMN1; SMN2NCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021129653-A1 | PROTEIN DEGRADATION AGENT COMPOUND PREPARATION METHOD AND APPLICATION | 上海济煜医药科技有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | ELAN PHARMACEUTICALS, INC. | 2006-04-27 | — | — | US | disclosed |
| US-5641778-A | EXHIBIT RENIN-INHIBITING PROPERTIES AND CAN BE USED AS ANTIHYPERTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1997-06-24 | — | — | US | disclosed |
| EP-0716077-A1 | Aromatically substituted omega amino alcanoic acid amides and alcanoic diamides and their use as renine inhibitors | CIBA-GEIGY AG (CH) | 1996-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089355-A1 | Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides | APP, BACE1, BACE2 | SMN1; SMN2 1043/4885CHRM1 138/4885CHRM3 310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.